Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy.

Bellibas SE, Siddique Z, Dorr A, Bertasso A, Sista P, Kolis SJ, Cotler S, Delora P; T20-310/NV16056 Study Group.

Pediatr Infect Dis J. 2004 Dec;23(12):1137-41.

PMID:
15626952
[PubMed - indexed for MEDLINE]
2.

Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.

Thompson M, DeJesus E, Richmond G, Wheeler D, Flaherty J, Piliero P, True A, Chiu YY, Zhang Y, McFalls E, Miralles GD, Patel IH.

AIDS. 2006 Feb 14;20(3):397-404.

PMID:
16439873
[PubMed - indexed for MEDLINE]
3.

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.

Ruxrungtham K, Boyd M, Bellibas SE, Zhang X, Dorr A, Kolis S, Kinchelow T, Buss N, Patel IH.

J Clin Pharmacol. 2004 Jul;44(7):793-803.

PMID:
15199084
[PubMed - indexed for MEDLINE]
4.

Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients.

Mould DR, Zhang X, Nieforth K, Salgo M, Buss N, Patel IH.

Clin Pharmacol Ther. 2005 Jun;77(6):515-28.

PMID:
15961983
[PubMed - indexed for MEDLINE]
5.

Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.

Lalezari JP, Patel IH, Zhang X, Dorr A, Hawker N, Siddique Z, Kolis SJ, Kinchelow T.

J Clin Virol. 2003 Oct;28(2):217-22.

PMID:
12957192
[PubMed - indexed for MEDLINE]
6.

Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment.

Zhang X, Lin T, Bertasso A, Evans C, Dorr A, Kolis SJ, Salgo M, Patel I; T20-310/NV16056 Study Group.

J Clin Pharmacol. 2007 Apr;47(4):510-7.

PMID:
17389560
[PubMed - indexed for MEDLINE]
7.

Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function.

Tebas P, Bellos N, Lucasti C, Richmond G, Godofsky E, Patel I, Chiu YY, Evans C, Rowell L, Salgo M.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):342-5.

PMID:
18091608
[PubMed - indexed for MEDLINE]
8.

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide.

Boyd MA, Zhang X, Dorr A, Ruxrungtham K, Kolis S, Nieforth K, Kinchelow T, Buss N, Patel IH.

J Clin Pharmacol. 2003 Dec;43(12):1382-91.

PMID:
14615475
[PubMed - indexed for MEDLINE]
9.

Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.

Wiznia A, Church J, Emmanuel P, Eppes S, Rowell L, Evans C, Bertasso A; T20-310 Study Group.

Pediatr Infect Dis J. 2007 Sep;26(9):799-805.

PMID:
17721374
[PubMed - indexed for MEDLINE]
10.

Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships.

Soy D, Aweeka FT, Church JA, Cunningham CK, Palumbo P, Kosel BW, Sheiner LB; Pediatric AIDS Clinical Trial Group (PACTG) Study P1005 Investigators.

Clin Pharmacol Ther. 2003 Dec;74(6):569-80.

PMID:
14663459
[PubMed - indexed for MEDLINE]
11.

Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.

Wheeler DA, Lalezari JP, Kilby JM, Wheat J, Delehanty J, DeMasi R, Patel I, Salgo M.

J Clin Virol. 2004 Jun;30(2):183-90.

PMID:
15125875
[PubMed - indexed for MEDLINE]
12.

Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.

Fung HB, Guo Y.

Clin Ther. 2004 Mar;26(3):352-78. Review.

PMID:
15110129
[PubMed - indexed for MEDLINE]
13.

Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition.

Zhang X, Nieforth K, Lang JM, Rouzier-Panis R, Reynes J, Dorr A, Kolis S, Stiles MR, Kinchelow T, Patel IH.

Clin Pharmacol Ther. 2002 Jul;72(1):10-9.

PMID:
12152000
[PubMed - indexed for MEDLINE]
14.

[Enfuvirtide, first fusion inhibitor in the treatment of human immunodeficiency virus infection: mechanism of action and pharmacokinetics].

Raffi F.

Med Mal Infect. 2004 Sep;34 Spec No 1:3-7. Review. French.

PMID:
15742549
[PubMed - indexed for MEDLINE]
15.

Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide.

Patel IH, Zhang X, Nieforth K, Salgo M, Buss N.

Clin Pharmacokinet. 2005;44(2):175-86. Review.

PMID:
15656696
[PubMed - indexed for MEDLINE]
16.

Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children.

Church JA, Hughes M, Chen J, Palumbo P, Mofenson LM, Delora P, Smith E, Wiznia A, Hawkins E, Sista P, Cunningham CK; Pediatric AIDS Clinical Trials Group P1005 Study Team.

Pediatr Infect Dis J. 2004 Aug;23(8):713-8.

PMID:
15295220
[PubMed - indexed for MEDLINE]
17.

Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration.

True AL, Chiu YY, Demasi RA, Stout R, Patel I.

Pharmacotherapy. 2006 Dec;26(12):1679-86.

PMID:
17125431
[PubMed - indexed for MEDLINE]
18.

Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor.

Mohanty U, Dixit NM.

J Theor Biol. 2008 Apr 7;251(3):541-51. doi: 10.1016/j.jtbi.2007.12.017. Epub 2007 Dec 28.

PMID:
18258267
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro.

Dai SJ, Dou GF, Qiang XH, Song HF, Tang ZM, Liu DS, Liu XW, Yang LM, Zheng YT, Liang Q.

Acta Pharmacol Sin. 2005 Oct;26(10):1274-80.

PMID:
16174446
[PubMed - indexed for MEDLINE]
Free Article
20.

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, Dusek A.

AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):685-93. Erratum in: AIDS Res Hum Retroviruses. 2003 Jan 1;19(1):83..

PMID:
12167274
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk